Micro-cap oncology biotech Lixte Biotechnology sets terms for $9 million Nasdaq uplisting

Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, announced terms for its IPO on Tuesday.

The East Setauket, NY-based company plans to raise $9 million by offering 1.5 million shares at a price range of $5.75 to $6.75, below the as-converted last close of its shares on the OTCQB (LIXT). At the midpoint of the proposed range, Lixte Biotechnology Holdings would command a fully diluted market value of $84 million.

The company has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series targets several types of cancer, with potential for vascular and metabolic diseases. The LB-200 series may be useful for the treatment of chronic hereditary diseases. The company completed a Phase 1 trial of LB-100 demonstrating antitumor activity in humans and is currently in a Phase 1b/2 trial, with results expected in 2023.

Lixte Biotechnology Holdings was founded in 2005 and plans to list on the Nasdaq under the symbol LIXT. WestPark Capital is the sole bookrunner on the deal.

The article Micro-cap oncology biotech Lixte Biotechnology sets terms for $9 million Nasdaq uplisting originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest IPOs Videos

    VersaBank Rings the Nasdaq Stock Market Closing Bell in Celebration of its IPO

    VersaBank (Nasdaq:VBNK), visits the Nasdaq MarketSite in Times Square.
    In honor of the occasion, David R. Taylor B.Sc. (Hons.), M.B.A., F.I.C.B., Director, President & CEO, rings the Closing Bell.

    Oct 5, 2021

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More